The use of sublingual nifedipine: a continuing concern.
Messerli
F H
FH
Department of Internal Medicine, Ochsner Clinic, New Orleans, LA 70121, USA.
Grossman
E
E
D000286:Administration, Sublingual; D000739:Anecdotes as Topic; D000789:Angina, Unstable / Q000188:drug therapy; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D002121:Calcium Channel Blockers / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D007022:Hypotension / Q000139:chemically induced*; D009543:Nifedipine / Q000008:administration & dosage* / Q000009:adverse effects*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D014665:Vasodilator Agents; D009543:Nifedipine